Key facts
- Alveo (Diagnostic Equipment)’s last known valuation is $116.0M (Mar 2021).
- It has raised $83.6M; the latest was Later Stage VC in Jun 2025.
- Notable investors include Gates Foundation, Celesta Capital, Black Diamond Ventures, Seed-Resolute, Opaleye — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Alveo (Diagnostic Equipment)
- ·The full record, as it builds
Funding rounds
No funding rounds for Alveo (Diagnostic Equipment) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Alveo (Diagnostic Equipment)
Developer of diagnostics technology designed to address global challenges and opportunities surrounding infectious diseases. The company's cloud-strengthened technology helps in the creation of vast datasets in order to track global infectious disease outbreaks and connect individuals with treatments, enabling consumers, healthcare professionals, and treatment providers with the ability to detect a range of diseases that threaten public health.
- Sector
- Healthcare
- HQ
- Alameda, CA, United States
- Founded
- 2014
- Employees
- 67
- Website
- alveotechnologies.com/
- Ownership
- Privately Held (backing)
Alveo (Diagnostic Equipment) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Alveo (Diagnostic Equipment) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Alveo (Diagnostic Equipment) in its N-PORT filings yet. We sweep new filings monthly.